Fundraising FoxAntegrin Therapeutics
St. Louis, US · Founded 2014 · Delaware corporation · 1 known investors
Find your way into Antegrin Therapeutics
Sign up to see every warm intro you have to Antegrin Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Antegrin Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
GH
George H. Capps, IIExecutive
RK
Robert KarrExecutive
DW
David W. GriggsNamed on SEC filing
TP
Thomas P. CirritoNamed on SEC filing
Board
CB
Charles BoltenBoard director
RD
MA
Michael A. YeadonBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$9.7M disclosed across 3 rounds · 2014–2017
▶$9MraisedAug 2017 · 6 investors · PharmaceuticalsRule 506(c)
▶$9MraisedAug 2017 · 6 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Bradford WilliamsonExecutive Officer
- Ben AuspitzDirector
- Scott SeiwertExecutive Officer
- Peter BarrettDirector
- George H. Capps IIExecutive Officer, Promoter
- Rajesh DevrajDirector
- Offering amount
- $26M
- Amount sold
- $9M
- First sale
- Jun 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06c
▶$100KraisedOct 2015 · 1 investors · PharmaceuticalsRule 506(c)
▶$100KraisedOct 2015 · 1 investors · Pharmaceuticals
Rule 506(c)Officers, directors & promoters on the filing
- Charles BoltenDirector
- George H. Capps, IIExecutive Officer
- Robert KarrExecutive Officer, Director
- Michael A. YeadonDirector
- David W. GriggsDirector
- Thomas P. CirritoDirector
- Rajesh DevrajDirector
- Offering amount
- $600K
- Amount sold
- $100K
- Minimum investment
- $1
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06c
▶$595.6KraisedOct 2015 · 5 investors · PharmaceuticalsRule 506(b)
▶$595.6KraisedOct 2015 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- George H. Capps, IIExecutive Officer
- David W. GriggsDirector
- Robert KarrExecutive Officer, Director
- Rajesh DevrajDirector
- Charles BoltenDirector
- Thomas P. CirritoDirector
- Michael YeadonDirector
- Offering amount
- $595.6K
- Amount sold
- $595.6K
- Minimum investment
- $1
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Antegrin Therapeutics's investors?
- Antegrin Therapeutics's investors include Atlas Venture.
- How much funding has Antegrin Therapeutics raised?
- Antegrin Therapeutics has disclosed $9.7M raised across 3 rounds.
- Where is Antegrin Therapeutics headquartered?
- Antegrin Therapeutics is headquartered in St. Louis, US.